Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression

Depression Clinical Trial

— CREST-MST  

Official title:

Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST - MST)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03191058
• Other study ID #: CREST-MST
• Secondary ID: 1R01MH112815-01
• Status: Active, not recruiting
• Phase: N/A
• Start date: June 26, 2018
• Est. completion date: November 7, 2024

Study information

• Verified date: May 2024
• Source: University of Texas Southwestern Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for depression. Even with multiple medication trials, 30 - 40% of patients will experience a pharmacologically resistant form of illness. The ineffectiveness of current treatments for major depressive disorder (MDD) coupled with the economic burden associated with the disorder engenders a need for novel therapeutic interventions that can provide greater response and remission rates.

Description:

The study will involve a randomized, double blind, non-inferiority clinical trial with two treatment arms conducted in two international academic medical centers (the Centre for Addiction and Mental Health in Toronto, Canada and UT Southwestern in Dallas, Texas). The investigators are pursuing a non-inferiority clinical trial in an effort to compare MST - a new treatment for TRD - to RUL-UB-ECT. Treatment will be administered two to three days per week. Depression symptoms will be assessed with the 24-item Hamilton Depression Rating Scale (HRSD-24) and suicidality will be assessed with the Scale for Suicidal Ideation (SSI). Remission will be defined as HRSD-24 < or = 10 and a > 60% decrease in scores from baseline on two consecutive ratings. Once a participant reaches remission, a second rating to confirm remission will be conducted immediately before their next scheduled treatment. If remission is confirmed, they will then be considered a completer of the acute treatment course. Remission of suicidal ideation is defined as a score of 0 on the SSI. Therefore, there will be no specific minimum number of treatments that patients must receive to be classified as remitters. However, patients who do not meet remission criteria after 21 treatment sessions will be considered non-remitters and will cease treatment sessions. This maximum treatment number was chosen allowing for the possibility that MST may require more treatment sessions to achieve remission, similar to RUL-UB ECT. The blind will not be broken to participants until the completion of the entire study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 219
• Est. completion date: November 7, 2024
• Est. primary completion date: April 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

Patients will be included if they:

1. are inpatients or outpatients;

2. are voluntary and competent to consent to treatment and research procedures according to ECT/MST attending psychiatrist;

3. have a MINI International Neuropsychiatric Interview diagnosis, Version 6 (MINI-6.0) diagnosis of non-psychotic MDD

4. are 18 years of age or older

5. have a baseline HRSD-24 score > or = 21;

6. are considered to be appropriate to receive convulsive therapy as assessed by an ECT attending psychiatrist and a consultant anaesthesiologist

7. are agreeable to keeping their current antidepressant treatment constant during the intervention;

8. are likely able to adhere to the intervention schedule;

9. meet the MST safety criteria [75];

10. If a woman of child-bearing potential: is willing to provide a negative pregnancy test and agrees not to become pregnant during trial participation.

Exclusion Criteria

Patients will be excluded if they:

1. have a history of MINI diagnosis of substance dependence or abuse within the past three months;

2. have a concomitant major unstable medical illness;

3. are pregnant or intend to get pregnant during the study;

4. have a MINI diagnosis of any primary psychotic disorder

5. have a MINI diagnosis of obsessive compulsive disorder, or post-traumatic stress disorder deemed to be primary and causing more functional impairment than the depressive disorder

6. have probable dementia based on study investigator assessment;

7. have any significant neurological disorder or condition likely to be associated with increased intracranial pressure or a space occupying brain lesion, e.g., cerebral aneurysm;

8. present with a medical condition, a medication, or a laboratory abnormality that could cause a major depressive episode or significant cognitive impairment in the opinion of the investigator (e.g., hypothyroidism with low TSH, rheumatoid arthritis requiring high dose prednisone, or Cushing's disease);

9. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed;

10. require a benzodiazepine with a dose > lorazepam 2 mg/day or equivalent or any anticonvulsant due to the potential of these medications to limit the efficacy of both MST and ECT;

11. are unable to communicate in English fluently enough to complete the neuropsychological tests;

12. have a non-correctable clinically significant sensory impairment (i.e., cannot hear or see well enough to complete the neuropsychological tests).

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Treatment-Resistant
• Seizures
• Treatment Resistant Depression
• Unipolar Depression

Intervention

Device:
• Magnetic Seizure Therapy
MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds). This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.
• Electroconvulsive Therapy
In the ECT arm treatment, the MECTA spectrum 5000Q or the MECTA Sigma devices will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes

Locations

Country	Name	City	State
Canada	Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health	Toronto	Ontario
United States	University of Texas Southwestern Medical Center	Dallas	Texas
United States	University of California San Diego	San Diego	California

Sponsors (4)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center	Centre for Addiction and Mental Health, National Institute of Mental Health (NIMH), University of California, San Diego

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement in symptom severity of depression as measured by the Hamilton Rating Scale for Depression - 24 (HRSD-24)	Hamilton Rating Scale for Depression (24-item version): This scale is used to quantify the severity of symptoms of depression; Scale range: 0-76 (total score); Lower scores indicate lower severity of depressive symptoms (i.e., better outcome); Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)	7 weeks
Primary	Cognitive adverse effects as indexed by the Autobiographical Memory Test (AMT)	Autobiographical Memory Test: -Interviewer-rated measure with 10 items that indexes autobiographical memory recall and specificity.	7 weeks
Secondary	Improvement in symptom severity of Suicidal Ideation as measured by the Scale for Suicidal Ideation (SSI)	Scale for Suicidal Ideation: This scale is used to assess the presence or absence of suicidal ideation and the degree of severity of suicidal ideas; Scale range: 0 - 38 (total score); Lower scores indicate lower severity of suicidal ideation (i.e., better outcome); Higher scores indicate higher severity of suicidal ideation (i.e., worse outcome)	7 weeks